Product
AKST4290
4 clinical trials
5 indications
Indication
Diabetic RetinopathyIndication
Parkinson's diseaseIndication
pemphigoidIndication
BullousIndication
Age-Related Macular DegenerationClinical trial
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)Status: Terminated, Estimated PCD: 2021-12-09
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic TreatmentStatus: Completed, Estimated PCD: 2021-02-11
Clinical trial
Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous PemphigoidStatus: Terminated, Estimated PCD: 2021-03-29
Clinical trial
A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 With Loading Doses of Aflibercept in Patients With Newly Diagnosed Neovascular Age-Related Macular DegenerationStatus: Completed, Estimated PCD: 2021-08-19